Physician profile
Jordon Backor
NPI 1073172417
$7,231.36
in general payments reported to CMS, 2019-2025
21 companies · $1,568 in 2025
The $1,568 reported for 2025 was more than what 89% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11.36 · 2022: $1,849 · 2023: $1,896 · 2024: $1,907 · 2025: $1,568.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,359 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,358.68 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,012.47 | 2022-2025 | Caplyta |
| Supernus Pharmaceuticals, INC. | $944.78 | 2022-2024 | Qelbree, Qelbree |
| Otsuka America Pharmaceutical, INC. | $901.82 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Corium, LLC | $740.79 | 2022-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $649.25 | 2022-2025 | Trintellix |
| Lundbeck LLC | $514.66 | 2022-2025 | Rexulti |
| Neos Therapeutics, Lp | $498.37 | 2022-2025 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Ironshore Pharmaceuticals INC. | $478.46 | 2022-2024 | Jornay Pm |
| Sunovion Pharmaceuticals INC. | $331.40 | 2022 | |
| Noven Therapeutics, LLC | $266.29 | 2022-2025 | Xelstrym, Secuado |
| Alkermes, INC. | $256.70 | 2022-2025 | Aristada, Lybalvi |
| Axsome Therapeutics, INC. | $222.20 | 2024-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $200.54 | 2023-2025 | Spravato, Invega Sustenna |
| Neurocrine Biosciences, INC. | $70.46 | 2024-2025 | Ingrezza |
| Validus Pharmaceuticals LLC | $44.66 | 2023-2025 | Raldesy, Equetro, Equetro |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $22.31 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $17.56 | 2024 | Cobenfy |
| Vertical Pharmaceuticals, LLC | $17.32 | 2025 | Relexxii |
| Almatica Pharma LLC | $16.41 | 2025 | Loreev Xr |
| Vanda Pharmaceuticals INC. | $13.55 | 2025 | Fanapt |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.36 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jordon Backor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.